UroToday - At 18-24 months post-brachytherapy for prostate cancer (CaP) it is not uncommon to have a transient rise in the PSA referred to as PSA bounce. This is possibly due to the delay in cell kill from brachytherapy, but is not well understood. The American Society for Therapeutic Radiology and Oncology (ASTRO) defines biochemical failure for CaP as 3 consecutive rises in the PSA. Dr. Toledano and associates investigated whether PSA bounce might mimic the ASTRO definition of failure and report their findings in the journal Brachytherapy.

Between 1999 and 2001 295 patients were treated with brachytherapy at the Paris Institute Curie/Hospital Cochin/Hospital Necker Paris group. Enrolled patients had clinical stage T1-T2 CaP, Gleason